Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer.
Colorectal cancer
Marker
Signaling pathway
Small mothers against decapentaplegic homologs
Transforming growth factor-beta
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Sep 2022
07 Sep 2022
Historique:
received:
12
05
2022
revised:
06
07
2022
accepted:
16
08
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
According to data from 2020, Slovakia has long been among the top five countries with the highest incidence rate of colorectal cancer (CRC) worldwide, and the rate is continuing to rise every year. In approximately 80% of CRC cases, allelic loss (loss of heterozygosity, LOH) occurs in the long arm of chromosome 18q. The most important genes that can be silenced by 18q LOH or mutations are small mothers against decapentaplegic homolog (SMAD) 2 and SMAD4, which are intracellular mediators of transforming growth factor (TGF)-β superfamily signals. TGF-β plays an important role in the pro-oncogenic processes, including such properties as invasion, epithelial-mesenchymal transition (commonly known as EMT), promotion of angiogenesis, and immunomodulatory effects. Several recent studies have reported that activation of TGF-β signaling is related to drug resistance in CRC. Because the mechanisms of drug resistance are different between patients in different stages of CRC, personalized treatment is more effective. Therefore, knowledge of the activation and inhibition of factors that affect the TGF-β signaling pathway is very important.
Identifiants
pubmed: 36156927
doi: 10.3748/wjg.v28.i33.4744
pmc: PMC9476856
doi:
Substances chimiques
Transforming Growth Factor beta
0
Transforming Growth Factor beta1
0
Transforming Growth Factors
76057-06-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4744-4761Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare having no conflict of interests for this article.
Références
Int J Cancer. 2003 Apr 20;104(4):446-9
pubmed: 12584741
World J Clin Cases. 2018 Dec 6;6(15):869-881
pubmed: 30568941
Cells. 2019 Sep 23;8(10):
pubmed: 31547567
Onco Targets Ther. 2018 Apr 05;11:1929-1939
pubmed: 29670368
Front Cell Dev Biol. 2021 Mar 16;9:659760
pubmed: 33796540
Acta Biochim Biophys Sin (Shanghai). 2018 Oct 1;50(10):941-949
pubmed: 30165534
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Front Oncol. 2021 Apr 14;11:626620
pubmed: 33937030
Gastroenterology. 2015 Jun;148(7):1276-9
pubmed: 25921376
Exp Mol Pathol. 2021 Dec;123:104714
pubmed: 34717960
Ann Transl Med. 2016 Aug;4(16):305
pubmed: 27668225
Cancer Discov. 2013 Oct;3(10):1172-89
pubmed: 23838884
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Signal Transduct Target Ther. 2018 Jun 8;3:15
pubmed: 29892481
Comput Struct Biotechnol J. 2020 Sep 17;18:2568-2572
pubmed: 33005315
Histopathology. 2019 May;74(6):873-882
pubmed: 30636020
Anticancer Res. 2016 Apr;36(4):1447-60
pubmed: 27069120
Cancer Res. 2013 Jan 15;73(2):725-35
pubmed: 23139211
J Clin Pathol. 2018 Aug;71(8):661-664
pubmed: 29720405
J Microbiol. 2022 Jul;60(7):659-667
pubmed: 35731347
Cancer Biol Ther. 2018 Feb 1;19(2):105-112
pubmed: 29219668
World J Gastroenterol. 2016 Feb 7;22(5):1745-55
pubmed: 26855534
J Mol Biol. 2019 Jul 12;431(15):2644-2654
pubmed: 31121181
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127396
pubmed: 32738967
Cell Death Dis. 2014 Feb 20;5:e1073
pubmed: 24556688
Biomed Pharmacother. 2020 Sep;129:110287
pubmed: 32540643
Mol Cancer. 2022 Feb 8;21(1):41
pubmed: 35135542
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188356
pubmed: 32147542
Onco Targets Ther. 2021 Dec 07;14:5391-5402
pubmed: 34908844
Gastroenterology. 2010 Jun;138(6):2059-72
pubmed: 20420946
Front Cell Dev Biol. 2020 Jul 08;8:605
pubmed: 32733895
Biomed Pharmacother. 2016 Oct;83:967-974
pubmed: 27522259
Oncogene. 2016 Aug 18;35(33):4388-98
pubmed: 26616859
Mol Cancer. 2020 Mar 4;19(1):51
pubmed: 32127004
J Gastrointest Oncol. 2020 Oct;11(5):918-931
pubmed: 33209488
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):
pubmed: 28246180
Front Cell Dev Biol. 2021 Nov 30;9:786728
pubmed: 34917620
PLoS One. 2019 Feb 7;14(2):e0212142
pubmed: 30730996
Ann Oncol. 2019 Nov 1;30(11):1796-1803
pubmed: 31868905
Oncol Res. 2019 Mar 29;27(4):399-406
pubmed: 29426374
World J Gastroenterol. 2017 Mar 14;23(10):1816-1827
pubmed: 28348487
Crit Rev Oncol Hematol. 2016 Mar;99:74-80
pubmed: 26702883
Int J Oncol. 2019 Oct;55(4):925-937
pubmed: 31432155
Cancer Cell Int. 2021 Sep 14;21(1):483
pubmed: 34521402
Cancers (Basel). 2021 Mar 11;13(6):
pubmed: 33799801
Mol Med Rep. 2019 Oct;20(4):3735-3745
pubmed: 31485652
Br J Surg. 2019 May;106(6):682-691
pubmed: 30945755
Chem Biol Interact. 2019 Feb 1;299:131-139
pubmed: 30543783
Biomed Pharmacother. 2021 Jul;139:111657
pubmed: 34243626
Can Respir J. 2019 Sep 19;2019:7157861
pubmed: 31641391
Cold Spring Harb Perspect Biol. 2017 Mar 1;9(3):
pubmed: 27920040
Histopathology. 2019 Oct;75(4):546-551
pubmed: 31054158
J Neurochem. 2020 May;153(4):525-538
pubmed: 31729763
Int J Biol Sci. 2018 Jan 12;14(2):111-123
pubmed: 29483830
PLoS One. 2017 Mar 7;12(3):e0173345
pubmed: 28267766
Cancers (Basel). 2020 Jul 13;12(7):
pubmed: 32668597
Int J Mol Sci. 2021 Apr 10;22(8):
pubmed: 33920230
Lancet Oncol. 2021 May;22(5):665-677
pubmed: 33812497
Cancers (Basel). 2019 May 01;11(5):
pubmed: 31052449
J Exp Clin Cancer Res. 2019 Jun 11;38(1):249
pubmed: 31186036
Oncol Lett. 2018 Mar;15(3):3971-3976
pubmed: 29467907
Phytomedicine. 2019 Mar 15;56:126-135
pubmed: 30668333
Crit Rev Biochem Mol Biol. 2020 Dec;55(6):691-715
pubmed: 33081543
Int J Mol Sci. 2013 Dec 05;14(12):23774-90
pubmed: 24317436
BMC Med Genomics. 2022 Jan 11;15(1):8
pubmed: 35016683
Cancer Rep (Hoboken). 2022 Jan;5(1):e1423
pubmed: 34114372
Sci Rep. 2016 Feb 24;6:21602
pubmed: 26905010
World J Gastroenterol. 2010 Dec 21;16(47):6026-34
pubmed: 21157981
Br J Dermatol. 2016 Jan;174(1):120-30
pubmed: 26301336
Int J Mol Med. 2021 Mar;47(3):
pubmed: 33655327
Transl Oncol. 2019 Mar;12(3):475-484
pubmed: 30594036
World J Gastrointest Oncol. 2022 Apr 15;14(4):748-764
pubmed: 35582099
Hum Vaccin Immunother. 2017 Aug 3;13(8):1741-1750
pubmed: 28575585
Mol Clin Oncol. 2017 Dec;7(6):943-952
pubmed: 29285354
Int J Mol Sci. 2021 Jan 06;22(2):
pubmed: 33418880
Biomedicines. 2021 Aug 24;9(9):
pubmed: 34572263
Acta Biomed. 2018 Dec 17;89(9-S):97-101
pubmed: 30561401
Gastroenterology. 2017 Jan;152(1):36-52
pubmed: 27773809
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):111-130
pubmed: 31900466
Int J Oncol. 2014 May;44(5):1643-51
pubmed: 24573038
Ann Transl Med. 2018 Jun;6(12):241
pubmed: 30069443
Gastroenterol Hepatol Bed Bench. 2021 Fall;14(Suppl1):S32-S40
pubmed: 35154600
Evid Based Complement Alternat Med. 2020 Jun 29;2020:5264651
pubmed: 32714407
Gastroenterology. 2021 Aug;161(2):434-452.e15
pubmed: 33940008
Front Biosci (Landmark Ed). 2012 Jan 01;17(4):1281-93
pubmed: 22201803
Mol Cell Biochem. 2016 Feb;413(1-2):109-18
pubmed: 26728998
Cancer Immunol Res. 2018 Aug;6(8):965-977
pubmed: 29915022
Oncol Lett. 2018 Jul;16(1):9-18
pubmed: 29928381
Int J Mol Med. 2018 Mar;41(3):1487-1499
pubmed: 29328420
Oncol Lett. 2017 Nov;14(5):6203-6209
pubmed: 29113268
Semin Cancer Biol. 2019 Apr;55:37-52
pubmed: 29775690
Ann Oncol. 2019 Apr 1;30(4):520-527
pubmed: 30796810
Med Sci Monit. 2018 Mar 20;24:1633-1641
pubmed: 29555895
Bioengineered. 2020 Dec;11(1):91-102
pubmed: 31906769
Exp Dermatol. 2015 May;24(5):355-60
pubmed: 25683490
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011
Front Pharmacol. 2022 Feb 28;13:791272
pubmed: 35295334
Front Pharmacol. 2020 Nov 18;11:558741
pubmed: 33364939
EBioMedicine. 2019 Mar;41:702-710
pubmed: 30808576
Int J Oncol. 2022 Jun;60(6):
pubmed: 35425991
Cancers (Basel). 2020 Apr 21;12(4):
pubmed: 32326239
J Oral Pathol Med. 2013 May;42(5):415-23
pubmed: 23157422
J Biol Chem. 2018 Aug 24;293(34):13059-13072
pubmed: 29907569
Cancer Cell Int. 2022 Jun 8;22(1):209
pubmed: 35676702
PLoS One. 2022 Apr 15;17(4):e0265901
pubmed: 35427373
Front Oncol. 2022 Feb 02;12:783079
pubmed: 35186731
Cancer Commun (Lond). 2021 Dec;41(12):1275-1313
pubmed: 34791817
Cell Death Dis. 2018 Feb 15;9(3):263
pubmed: 29449642
Mol Cancer. 2020 Jul 27;19(1):117
pubmed: 32713345
J Clin Invest. 2001 Aug;108(4):601-9
pubmed: 11518734
Clin Cancer Res. 2018 Jul 1;24(13):3176-3185
pubmed: 29602802